The next experiment is on the way

Sep 2024

Nutaria is entering a pivotal phase with its Preclinical Dose Optimization Study (PDOS) for NT501, already approved at LIOS. This study will determine the ideal dosing and timing for our NT501 Parkinson’s treatment, providing critical insights on its interaction with key brain structures. With these results, Nutaria is confidently moving toward clinical trials, marking a transformative step in the treatment of Parkinson’s disease.

April, 2024

Nutaria has successfully completed two consecutive animal studies, validating the targeted delivery of NT501. Conducted by the independent European preclinical Contract Research Organization (CRO), LIOS, these studies demonstrated the effective intranasal delivery of Nutaria’s nanoparticles to key brain structures in a sample of 52 rats. The results confirm the precision and efficacy of our delivery system, laying the foundation for the next phase of our development.

September, 2022
Remarkable results from Nutaria’s first in vitro study of NT501, conducted in September 2022, marked a significant milestone in validating our targeted delivery technology. This study, performed by an independent preclinical CRO using human neuroectodermal cell lines provided by Nutaria, demonstrated that cells expressing receptors for NT501’s coating ingredients internalized the active compound far more effectively. This was confirmed through the detection of elevated levels of phosphorylated cells, highlighting the enhanced efficacy of our delivery system

The next experiment is on the way

Subscribe to get exclusive updates